Alps Group Inc (NASDAQ: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its financial results for the year ended March 31, 2026, and provides a business update.
Completed the Business Combination with Globalink in October 2025 and began trading on the NASDAQ Global Market under the ticker symbol “ALPS”.
"Fiscal year 2026 was a transformational year for Alps. We completed our Business Combination with Globalink Investment Inc. and began trading on the Nasdaq Global Market under the ticker symbol 'ALPS,' giving us a stronger platform to execute against our long-term strategy," said Dr. Tham Seng Kong, Managing Director and Group Chief Executive Officer of Alps Group Inc. "At the same time, we grew revenue 44% year-over-year, advanced our cellular therapy pipeline and sharpened our research and development focus on the areas where we see the greatest opportunity to deliver value for patients and shareholders."
ALPS shares gained 0.09 cents, or 2.1%, to 42 cents.
